Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter A Prieto

Showing results (41-50 of 45) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 45 results.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Cancer Discovery|December 2, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Nature Medicine|July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.
Pageof 5

Showing results (41-50 of 45) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 45 results.
Science Translational Medicine|March 3, 2017
Integrated molecular analysis of tumor biopsies on sequential CTLA-4 and PD-1 blockade reveals markers of response and resistanceWhijae Roh, Pei-Ling Chen, Alexandre Reuben, et al.
Cancer Discovery|December 2, 2025
Editor's Note: Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
Cancer Discovery|June 16, 2016
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint BlockadePei-Ling Chen, Whijae Roh, Alexandre Reuben, et al.
NPJ Genomic Medicine|August 19, 2017
Genomic and immune heterogeneity are associated with differential responses to therapy in melanomaAlexandre Reuben, Christine N Spencer, Peter A Prieto, et al.
Nature Medicine|July 9, 2021
Gut microbiota signatures are associated with toxicity to combined CTLA-4 and PD-1 blockadeMiles C Andrews, Connie P M Duong, Vancheswaran Gopalakrishnan, et al.
Pageof 5